A retrospective chart review of 49 patients taking 1 to 2 IOP-lowering treatments at the time of switching to latanoprostene bunod (LBN) found LBN produced approximately 25% additional IOP reduction.

The main study outcome was IOP change from the index visit to each of the next 2 chart-recorded follow-up visits, according to a report in Clinical Ophthalmology. Latanoprostene bunod produced an additional IOP reduction of approximately 25%, whether considering the overall data set, the subgroup of patients previously on a prostaglandin analog (PGA) plus another IOP-lowering product, or the subgroup of patients previously on a PGA alone. LBN appeared well tolerated with no new safety signals.

“These data may help inform clinicians on the potential effectiveness of LBN when switching patients with mild-to-moderate open-angle glaucoma or ocular hypertension from a prior PGA to LBN,” Constance Okeke, MD, and colleagues wrote.